Daniel O’Connell

Company: Tome Biosciences

Job title: VP

Seminars:

Panel Discussion: Ensuring Orthogonal Validation of Unintentional Edits 9:30 am

Benchmarking the benefits and limitations of key sequencing and PCR tools for determining on- and off-target editing outcomes Assessing the latest technologies for detecting on- and off-targets How do I effectively combine a range of these assays for a robust orthogonal approach? Assessing the role of patient sequencing in the clinical settingRead more

day: Conference Day Two

Large Serine Integrase Off-target Discovery and Validation for Therapeutic Human Genome Editing 8:30 am

Large serine integrases (LSIs) have emerged as an attractive therapeutic modality for the site specific genomic integration of DNA because they are sequence specific, size independent and do not rely on endogenous DNA repair mechanisms New technologies and computational methods that account for all potential unintended genome editing related to LSIs are required to advance…Read more

day: Conference Day Two